Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
KRX:207940
Price:
1 691 000
KRW
69.1%
Market Cap:
78.3T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Samsung Biologics Co Ltd
1691000
+691000.0001 (+69.1%)
| 52 Week Range |
946 000
1 691 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
Delete Alert
This alert will be permanently deleted.
Balance Sheet
Balance Sheet Decomposition
Samsung Biologics Co Ltd
Samsung Biologics Co Ltd
| Current Assets | 6.4T |
| Cash & Short-Term Investments | 1.9T |
| Receivables | 1.2T |
| Other Current Assets | 3.3T |
| Non-Current Assets | 12T |
| Long-Term Investments | 60.8B |
| PP&E | 6.2T |
| Intangibles | 5.4T |
| Other Non-Current Assets | 336.4B |
| Current Liabilities | 3.8T |
| Accounts Payable | 296.9B |
| Accrued Liabilities | 644.8B |
| Short-Term Debt | 152B |
| Other Current Liabilities | 2.7T |
| Non-Current Liabilities | 2.4T |
| Long-Term Debt | 896.1B |
| Other Non-Current Liabilities | 1.5T |
Balance Sheet
Samsung Biologics Co Ltd
Samsung Biologics Co Ltd
Currency: KRW
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
104 400
|
96 287
|
34 510
|
230 338
|
358 088
|
17 622
|
125 101
|
28 850
|
47 410
|
890 820
|
367 937
|
391 222
|
|
| Cash Equivalents |
104 400
|
96 287
|
34 510
|
230 338
|
358 088
|
17 622
|
125 101
|
28 850
|
47 410
|
890 820
|
367 937
|
391 222
|
|
| Short-Term Investments |
0
|
0
|
0
|
970 000
|
0
|
1 090 081
|
530 040
|
800 046
|
1 300 040
|
2 280 885
|
1 654 513
|
907 350
|
|
| Total Receivables |
6 324
|
28 694
|
37 009
|
75 631
|
25 817
|
141 833
|
207 930
|
246 197
|
430 242
|
820 156
|
742 712
|
1 246 732
|
|
| Accounts Receivables |
178
|
15 266
|
35 031
|
69 609
|
19 355
|
135 951
|
205 873
|
245 797
|
430 242
|
820 156
|
742 712
|
1 246 732
|
|
| Other Receivables |
6 146
|
13 428
|
1 978
|
6 022
|
6 462
|
5 881
|
2 057
|
400
|
0
|
0
|
0
|
0
|
|
| Inventory |
39 708
|
74 402
|
119 177
|
164 220
|
209 987
|
302 361
|
452 470
|
645 960
|
1 012 871
|
2 375 819
|
2 641 368
|
2 818 276
|
|
| Other Current Assets |
5 964
|
17 455
|
2 157
|
21 237
|
27 103
|
25 788
|
40 720
|
30 293
|
32 613
|
89 977
|
115 457
|
154 538
|
|
| Total Current Assets |
156 395
|
216 838
|
192 854
|
1 461 425
|
620 995
|
1 577 684
|
1 356 262
|
1 751 347
|
2 823 175
|
6 457 657
|
5 521 988
|
5 518 118
|
|
| PP&E Net |
377 647
|
761 294
|
890 256
|
1 090 960
|
1 513 333
|
1 717 721
|
1 718 911
|
1 760 728
|
2 227 687
|
3 871 452
|
4 342 424
|
5 837 482
|
|
| PP&E Gross |
377 647
|
761 294
|
890 256
|
1 090 960
|
1 513 333
|
1 717 721
|
1 718 911
|
1 760 728
|
2 227 687
|
3 871 452
|
4 342 424
|
5 837 482
|
|
| Accumulated Depreciation |
12 890
|
36 257
|
51 490
|
107 274
|
171 109
|
256 228
|
376 961
|
506 623
|
647 011
|
817 873
|
1 057 354
|
1 330 143
|
|
| Intangible Assets |
116 673
|
312 219
|
14 286
|
14 045
|
18 999
|
19 982
|
21 828
|
23 345
|
32 172
|
4 283 699
|
4 154 480
|
3 887 695
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1 677 608
|
1 677 608
|
1 677 608
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
77 079
|
131 071
|
197 863
|
193 759
|
188 262
|
254 469
|
309 936
|
|
| Long-Term Investments |
0
|
53 922
|
4 837 539
|
4 944 356
|
5 008 234
|
2 561 803
|
2 673 493
|
2 654 676
|
2 661 309
|
30 775
|
40 096
|
59 220
|
|
| Other Long-Term Assets |
8 846
|
11 425
|
25 559
|
22 230
|
21 530
|
26 140
|
10 063
|
36 242
|
31 907
|
72 598
|
55 133
|
46 238
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1 677 608
|
1 677 608
|
1 677 608
|
|
| Total Assets |
659 561
N/A
|
1 355 698
+106%
|
5 960 494
+340%
|
7 533 016
+26%
|
7 183 091
-5%
|
5 980 409
-17%
|
5 911 627
-1%
|
6 424 201
+9%
|
7 970 011
+24%
|
16 582 050
+108%
|
16 046 197
-3%
|
17 336 296
+8%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
2 638
|
957
|
358
|
1 521
|
14 479
|
3 811
|
12 290
|
54 984
|
32 251
|
59 616
|
208 278
|
726 420
|
|
| Accrued Liabilities |
42 502
|
62 005
|
28 341
|
23 046
|
28 670
|
49 777
|
43 876
|
64 356
|
74 322
|
207 437
|
281 317
|
545 403
|
|
| Short-Term Debt |
52 009
|
48 526
|
10 109
|
0
|
40 000
|
90 000
|
150 000
|
30 000
|
50 000
|
582 783
|
654 500
|
207 000
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
403 694
|
98 677
|
296 583
|
254 899
|
167 440
|
117 392
|
698 264
|
877 436
|
258 594
|
|
| Other Current Liabilities |
72 080
|
125 306
|
1 872 861
|
2 048 284
|
2 105 616
|
270 359
|
229 440
|
272 521
|
833 330
|
2 633 441
|
2 136 331
|
2 115 771
|
|
| Total Current Liabilities |
169 230
|
236 794
|
1 911 669
|
2 476 545
|
2 287 442
|
710 530
|
690 505
|
589 301
|
1 107 295
|
4 181 542
|
4 157 861
|
3 853 188
|
|
| Long-Term Debt |
71 000
|
427 199
|
681 792
|
439 363
|
407 236
|
486 113
|
248 808
|
587 465
|
1 125 355
|
1 232 986
|
377 397
|
1 020 645
|
|
| Deferred Income Tax |
0
|
0
|
581 574
|
526 671
|
505 316
|
534 542
|
470 545
|
449 847
|
487 712
|
1 214 216
|
1 184 420
|
972 062
|
|
| Minority Interest |
29 406
|
32 592
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
200
|
207
|
|
| Other Liabilities |
34 868
|
60 973
|
10 624
|
8 058
|
6 647
|
93 755
|
147 315
|
198 804
|
258 547
|
968 833
|
495 827
|
585 518
|
|
| Total Liabilities |
304 504
N/A
|
757 558
+149%
|
3 185 660
+321%
|
3 450 637
+8%
|
3 206 640
-7%
|
1 824 940
-43%
|
1 557 173
-15%
|
1 825 418
+17%
|
2 978 909
+63%
|
7 597 576
+155%
|
6 215 705
-18%
|
6 431 620
+3%
|
|
| Equity | |||||||||||||
| Common Stock |
59 435
|
101 833
|
137 844
|
165 413
|
165 413
|
165 413
|
165 413
|
165 413
|
165 413
|
177 935
|
177 935
|
177 935
|
|
| Retained Earnings |
218 755
|
314 664
|
1 601 530
|
1 424 707
|
1 327 735
|
1 509 719
|
1 712 623
|
1 953 598
|
2 347 187
|
3 145 601
|
4 003 293
|
5 086 609
|
|
| Additional Paid In Capital |
516 719
|
808 874
|
1 039 891
|
2 496 583
|
2 496 583
|
2 496 583
|
2 496 583
|
2 496 627
|
2 496 627
|
6 523 004
|
6 523 004
|
6 523 004
|
|
| Unrealized Security Profit/Loss |
0
|
15 229
|
9 664
|
11 368
|
4 601
|
5 564
|
5 433
|
3 695
|
4 177
|
4 992
|
0
|
0
|
|
| Other Equity |
2 342
|
13 132
|
14 095
|
15 691
|
17 880
|
21 811
|
25 598
|
20 549
|
22 302
|
867 058
|
873 739
|
882 872
|
|
| Total Equity |
355 058
N/A
|
598 140
+68%
|
2 774 834
+364%
|
4 082 379
+47%
|
3 976 451
-3%
|
4 155 468
+5%
|
4 354 454
+5%
|
4 598 783
+6%
|
4 991 102
+9%
|
8 984 474
+80%
|
9 830 492
+9%
|
10 904 676
+11%
|
|
| Total Liabilities & Equity |
659 561
N/A
|
1 355 698
+106%
|
5 960 494
+340%
|
7 533 016
+26%
|
7 183 091
-5%
|
5 980 409
-17%
|
5 911 627
-1%
|
6 424 201
+9%
|
7 970 011
+24%
|
16 582 050
+108%
|
16 046 197
-3%
|
17 336 296
+8%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
36
|
36
|
36
|
44
|
44
|
44
|
44
|
44
|
44
|
46
|
46
|
46
|
|
Switch to:
Switch to:
See Also
Discover More
